Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06070740 | First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma | recruiting | Phase 2 | 22 | Peking Union Medical College HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06068023 | The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.(ADAPTA) | recruiting | — | 400 | Fondazione Poliambulanza Istituto OspedalieroOTHER | 1 |
| Oct 5, 2023 |
| clinicaltrials |
| NCT06065891 | Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer(PALN) | recruiting | N/A | 300 | Jon UnossonOTHER | 2 | Oct 4, 2023 | clinicaltrials |
| NCT06056115 | Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic | recruiting | N/A | 20 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06056336 | Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 73 | Guo XufengOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06044506 | Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma | recruiting | Phase 1 | 3 | Dr Cipto Mangunkusumo General HospitalOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06055010 | Improving Pancreatic Cancer Care by the Use of Computational Science and Technology(IMPACT) | recruiting | — | 5,000 | UMC UtrechtOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05438836 | Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer(ROAR-A) | recruiting | — | 205 | Herlev HospitalOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT05994859 | SIRT for Potentially Resectable HCC | recruiting | N/A | 35 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06035016 | Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer | recruiting | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06031246 | Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018) | recruiting | Phase 3 | 634 | Fudan UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05980702 | 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC(HNC-SYSU-002) | recruiting | Phase 2 | 192 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05047510 | GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma | recruiting | N/A | 60 | Chinese Academy of SciencesOTHER_GOV | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06015802 | Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors | recruiting | — | 300 | Sun Yat-sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05502198 | Relevance of Sarcopenia in Advanced Liver Disease(ACCESS-ESLD) | recruiting | — | 150 | Linkoeping UniversityOTHER_GOV | 1 | Aug 24, 2023 | clinicaltrials |
| NCT06006650 | Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell | recruiting | Phase 2 | 114 | Tang-Du HospitalOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT05984342 | Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma | recruiting | Phase 1 | 50 | Affiliated Cancer Hospital of Shantou University Medical CollegeOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05980715 | PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy(HNC-SYSU-003) | recruiting | Phase 3 | 324 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05623267 | Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT(SURPASS) | recruiting | Phase 2 / Phase 3 | 346 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT04722692 | Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ(SENTINOT_2) | recruiting | Phase 3 | 500 | Uppsala UniversityOTHER | 3 | Aug 3, 2023 | clinicaltrials |
| NCT05838053 | Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | recruiting | — | 446 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05830500 | Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma | recruiting | Phase 4 | 360 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 25, 2023 | clinicaltrials |
| NCT05954897 | Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 29 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05862168 | Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial | recruiting | Phase 2 | 30 | Weijia Fang, MDOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05945407 | Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer | recruiting | N/A | 57 | Peking University People's HospitalOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05941338 | Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC(HNC-SYSU-001) | recruiting | Phase 2 | 100 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05935189 | Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens(TIR-HCC) | recruiting | — | 500 | Nikomed Medical CenterNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05926726 | GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | recruiting | N/A | 12 | RenJi HospitalOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05916755 | Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform(PORTRAIT) | recruiting | — | 100 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05917431 | Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC | recruiting | Phase 2 | 39 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05649865 | Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV)(MER-HPV) | recruiting | — | 150 | Region SkaneOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05608200 | Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC | recruiting | Phase 3 | 427 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05872880 | TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma. | recruiting | — | 124 | Xiangya Hospital of Central South UniversityOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT05083247 | Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma(STEREOPAC) | recruiting | Phase 2 | 256 | Erasme University HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05870969 | Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)(dSEARCH) | recruiting | — | 20,000 | Ruijin HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05447702 | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | recruiting | Phase 2 | 35 | West China HospitalOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05862337 | Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. | recruiting | Phase 3 | 480 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 17, 2023 | clinicaltrials |
| NCT05203120 | A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma | recruiting | N/A | 50 | University of AarhusOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05854823 | The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR | recruiting | N/A | 23 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT04539977 | PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer | recruiting | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05817903 | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients(AxIn) | recruiting | Phase 2 | 118 | Consorzio OncotechOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT05834764 | Pyrotinib in Women With High-risk in Early Stage Breast Cancer | recruiting | Phase 2 | 188 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT04807140 | Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) | recruiting | Phase 2 | 57 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT04992559 | A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC | recruiting | Phase 2 | 41 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05813015 | Study of Comparing of With and Without Sequential Therapy of S-1 | recruiting | Phase 3 | 70 | Zhejiang UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT04047953 | Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma | recruiting | N/A | 95 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05797493 | Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer(PICASSO) | recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05243082 | Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms(ERFA-PNET) | recruiting | N/A | 20 | Oslo University HospitalOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05054296 | Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring | recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05740995 | Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | recruiting | — | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 6, 2023source: clinicaltrials